268 related articles for article (PubMed ID: 31359259)
1. The Role of PI3K Inhibition in Lymphoid Malignancies.
von Keudell G; Moskowitz AJ
Curr Hematol Malig Rep; 2019 Oct; 14(5):405-413. PubMed ID: 31359259
[TBL] [Abstract][Full Text] [Related]
2. PI3K Inhibitors and Their Role as Novel Agents for Targeted Therapy in Lymphoma.
Sapon-Cousineau V; Sapon-Cousineau S; Assouline S
Curr Treat Options Oncol; 2020 Apr; 21(6):51. PubMed ID: 32356174
[TBL] [Abstract][Full Text] [Related]
3. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
Plosker GL; Figgitt DP
Drugs; 2003; 63(8):803-43. PubMed ID: 12662126
[TBL] [Abstract][Full Text] [Related]
4. NF-κB signaling pathway and its potential as a target for therapy in lymphoid neoplasms.
Yu L; Li L; Medeiros LJ; Young KH
Blood Rev; 2017 Mar; 31(2):77-92. PubMed ID: 27773462
[TBL] [Abstract][Full Text] [Related]
5. Phosphatidylinositol-3-Kinase Inhibition in Follicular Lymphoma.
Lynch RC; Gopal AK
Hematol Oncol Clin North Am; 2020 Aug; 34(4):727-741. PubMed ID: 32586577
[TBL] [Abstract][Full Text] [Related]
6. Molecularly-targeted Strategy and NF-κB in lymphoid malignancies.
Horie R
J Clin Exp Hematop; 2013; 53(3):185-95. PubMed ID: 24369220
[TBL] [Abstract][Full Text] [Related]
7. The role of PI3K inhibitors in the treatment of malignant lymphomas.
Berning P; Lenz G
Leuk Lymphoma; 2021 Mar; 62(3):517-527. PubMed ID: 33135516
[TBL] [Abstract][Full Text] [Related]
8. Exploring a Future for PI3K Inhibitors in Chronic Lymphocytic Leukemia.
Patel K; Pagel JM
Curr Hematol Malig Rep; 2019 Aug; 14(4):292-301. PubMed ID: 31203516
[TBL] [Abstract][Full Text] [Related]
9. Idelalisib: Targeting the PI3 Kinase Pathway in Non-Hodgkin Lymphoma.
Sujobert P; Rioufol C; Salles GA
Cancer J; 2016; 22(1):12-6. PubMed ID: 26841011
[TBL] [Abstract][Full Text] [Related]
10. Targeting PI3-kinase (PI3K), AKT and mTOR axis in lymphoma.
Blachly JS; Baiocchi RA
Br J Haematol; 2014 Oct; 167(1):19-32. PubMed ID: 25100567
[TBL] [Abstract][Full Text] [Related]
11. Approved and emerging PI3K inhibitors for the treatment of chronic lymphocytic leukemia and non-Hodgkin lymphoma.
Kienle DL; Stilgenbauer S
Expert Opin Pharmacother; 2020 Jun; 21(8):917-929. PubMed ID: 32162560
[TBL] [Abstract][Full Text] [Related]
12. Novel Agents Beyond Immunomodulatory Agents and Phosphoinositide-3-Kinase for Follicular Lymphoma.
Chin CK; Nastoupil LJ
Hematol Oncol Clin North Am; 2020 Aug; 34(4):743-756. PubMed ID: 32586578
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of idelalisib for the treatment of indolent B-cell malignancies.
Smolewski P; Rydygier D
Expert Opin Pharmacother; 2020 Oct; 21(15):1915-1926. PubMed ID: 32686971
[TBL] [Abstract][Full Text] [Related]
14. Copanlisib in the treatment of non-Hodgkin lymphoma.
Narkhede M; Cheson BD
Future Oncol; 2020 Sep; 16(26):1947-1955. PubMed ID: 32658557
[TBL] [Abstract][Full Text] [Related]
15. Is There a Role for Dual PI3K/mTOR Inhibitors for Patients Affected with Lymphoma?
Tarantelli C; Lupia A; Stathis A; Bertoni F
Int J Mol Sci; 2020 Feb; 21(3):. PubMed ID: 32033478
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic potential of PI3K signaling in distinct entities of B-cell lymphoma.
Wullenkord R; Friedrichs B; Erdmann T; Lenz G
Expert Rev Hematol; 2019 Dec; 12(12):1053-1062. PubMed ID: 31583927
[No Abstract] [Full Text] [Related]
17. Role of Bruton's tyrosine kinase in B cells and malignancies.
Pal Singh S; Dammeijer F; Hendriks RW
Mol Cancer; 2018 Feb; 17(1):57. PubMed ID: 29455639
[TBL] [Abstract][Full Text] [Related]
18. SHC014748M, a novel selective inhi-bitor of PI3Kδ, demonstrates promising preclinical antitumor activity in B cell lymphomas and chronic lymphocytic leukemia.
Fan L; Wang C; Zhao L; Wang Z; Zhang X; Liu X; Cao L; Xu W; Li J
Neoplasia; 2020 Dec; 22(12):714-724. PubMed ID: 33142237
[TBL] [Abstract][Full Text] [Related]
19. Phosphoinositide 3-Kinase Signaling in the Tumor Microenvironment: What Do We Need to Consider When Treating Chronic Lymphocytic Leukemia With PI3K Inhibitors?
Aydin E; Faehling S; Saleh M; Llaó Cid L; Seiffert M; Roessner PM
Front Immunol; 2020; 11():595818. PubMed ID: 33552053
[TBL] [Abstract][Full Text] [Related]
20. Properties of FDA-approved small molecule phosphatidylinositol 3-kinase inhibitors prescribed for the treatment of malignancies.
Roskoski R
Pharmacol Res; 2021 Jun; 168():105579. PubMed ID: 33774181
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]